Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Authors||Mehlman C, Chaabane N, Lacave R, Kerrou K, Ruppert AM, Cadranel J, Fallet V|
|Title||Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.|
|Journal||Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|ALK||T1151R||missense||unknown||ALK T1151R lies within the protein kinase domain of the Alk protein (UniProt.org). T1151R has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK rearrangement (PMID: 31027750), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Dec 2022).||Y|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK rearrange ALK T1151R||lung adenocarcinoma||predicted - resistant||Ceritinib||Case Reports/Case Series||Actionable||In a clinical case study, ALK T1151R was identified on post-progression biopsy in a patient with lung adenocarcinoma harboring an ALK rearrangement who had been on Zykadia (ceritinib) treatment for 6 months (PMID: 31027750).||31027750|
|ALK rearrange ALK T1151R||lung adenocarcinoma||predicted - sensitive||Brigatinib||Case Reports/Case Series||Actionable||In a clinical case study, Alunbrig (brigatinib) treatment resulted in clinical improvement and a major response in tumor volume and metabolic activity in a patient with metastatic lung adenocarcinoma harboring an ALK rearrangement and ALK T1151R until disease progression 3 months later (PMID: 31027750).||31027750|